Immunicon Corporation Announces Availability of Fluorescence In-Situ Hybridization Product Portfolio
08 April 2008 - 1:00PM
Business Wire
Immunicon Corporation (NASDAQ:IMMC) announced today the
availability of a new product portfolio for Fluorescence In-Situ
Hybridization (FISH) testing. The new RF Poseidon� FISH Probes are
available to the life science and diagnostic clinical laboratories.
FISH probes are used to detect gene amplification, gene
rearrangements, microdeletions, chromosome duplications and other
genetic abnormalities. �By eliminating the repeat sequences in the
FISH probes, the RF Poseidon FISH probes allow for a faster
hybridization, reduces background and provides more crisp signals
than current probes,� stated Leon Terstappen, MD, PhD, Chief
Scientific Officer, Immunicon Corporation. �Additionally, we
believe the faster assays allow scientists and laboratorians the
flexibility to obtain results in about 75% less time than current
practices today.� �The addition of the RF Poseidon FISH probe
portfolio to Immunicon�s products expands our molecular diagnostics
offering to customers,� said Byron Hewett, President & CEO,
Immunicon Corporation. �It allows Immunicon to fully expand into
rare cell testing arenas where we believe there are increasing
medical needs.� The RF Poseidon FISH Probes are developed using the
proprietary Repeat-Free� technology developed by Immunicon and the
ULS labeling system developed by Kreatech Diagnostics, the
Netherlands. The FISH probes are sold by Immunicon Corporation in
North America and manufactured and sold by Kreatech Diagnostics in
the rest of the world under an agreement entered into by Immunicon
and Kreatech in April 2007. Fluorescence In-Situ Hybridization
(FISH) Fluorescence In-Situ Hybridization is a technique used to
look at chromosomes (the parts of the cell that contain genetic
information in the form of DNA) or genes (specific regions of DNA
in chromosomes that make RNA and proteins). Pieces of DNA
containing a fluorescent dye are labeled and added to cells on a
glass slide. When viewed under a fluorescent microscope, parts of
chromosomes or genes that bind the pieces of DNA show up as
colored. FISH is routinely used in an increasing number of
molecular diagnostic areas, including disease diagnosis,
therapeutic targeting, drug development, gene mapping and
karyotyping analysis. FISH specifically is used to detect gene
amplification, gene rearrangements, microdeletions, chromosome
duplications and viral infections. About Immunicon Corporation
Immunicon Corporation is developing and commercializing proprietary
cell- and molecular-based human diagnostic and life science
research products, and is providing certain analytical services to
pharmaceutical and biotechnology companies to assist them in
developing new therapeutic agents, with an initial focus on cancer
disease management. Immunicon has developed platform technologies
to identify, count and characterize a small number of rare cells in
blood, such as circulating tumor cells and circulating endothelial
cells that are important in many diseases and biological processes.
Immunicon�s products and underlying technology platforms also have
application in the clinical development of cancer drugs and in
cancer research and may have applications in other fields of
medicine, such as cardiovascular and infectious diseases. For more
information, visit www.immunicon.com or
www.poseidondiagnostics.com. Forward-Looking Statements The
information contained in this press release includes
�forward-looking statements� within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are often preceded by words such as �hope,� �may,�
�believe,� �anticipate,� �plan,� �expect,� �intend,� �assume,�
�will� and similar expressions. Forward-looking statements
contained in this press release include, among others, statements
relating to Immunicon�s key product and clinical development
programs, the anticipated clinical utility of Immunicon�s products,
and other statements not of historical fact. Immunicon cautions
investors not to place undue reliance on the forward-looking
statements contained in this press release. Forward-looking
statements speak only as of the date of this press release, reflect
management�s current expectations and involve certain factors, such
as risks and uncertainties that may cause actual results to be far
different from those suggested by Immunicon�s forward-looking
statements. These factors include, but are not limited to, risks
and uncertainties associated with adequate financing of Immunicon
to continue as a going-concern; Immunicon�s dependence on Veridex,
LLC, a Johnson & Johnson company; the risks and uncertainties
associated with the arbitration proceeding with Veridex and the
award in favor of Veridex given Immunicon�s dependence on Veridex;
research and development and clinical trial expenditures;
commercialization of Immunicon�s product candidates; Immunicon�s
ability to use licensed products and to obtain new licenses from
third parties; Immunicon�s ability to manage its growth; obtaining
necessary regulatory approvals; reliance on third party
manufacturers and suppliers; reimbursement by third party payors to
Immunicon�s customers for Immunicon�s products; risks and
uncertainties associated with Immunicon�s outstanding convertible
notes and warrants; compliance with applicable manufacturing
standards; the ability to earn license and milestone payments under
Immunicon�s agreement with Veridex; retaining key management or
scientific personnel; delays in the development of new products or
to planned improvements to Immunicon�s products; effectiveness of
Immunicon�s products compared to competitors� products; protection
of Immunicon�s intellectual property and other proprietary rights;
conflicts with the intellectual property of third parties; product
liability lawsuits that may be brought against Immunicon; labor,
contract or technical difficulties; and competitive pressures in
Immunicon�s industry. These factors are discussed in more detail in
Immunicon�s filings with the Securities and Exchange Commission.
Except as required by law, Immunicon accepts no responsibility for
updating the information contained in this press release beyond the
published date, whether as a result of new information, future
events or otherwise, or for modifications made to this document by
Internet or wire services. �Immunicon� and the Immunicon
Corporation logo are registered trademarks of Immunicon
Corporation. Repeat-Free and CellTracks are trademarks of
Immunivest Corporation, a wholly-owned subsidiary of Immunicon
Corporation. All other trademarks or servicemarks appearing herein
are the property of their respective holders. ALL RIGHTS RESERVED.
Immunicon (NASDAQ:IMMC)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Immunicon (NASDAQ:IMMC)
Historical Stock Chart
Von Jun 2023 bis Jun 2024